OpenMFM · All presentationsEvidence review · 2025 paper

Critical appraisal · Journal club

Prenatal exome sequencing in structurally normal fetuses

What does a molecular finding tell us when fetal anatomy is reassuring?

MATERNAL–FETAL MEDICINE · GENOMICS · EVIDENCE REVIEW

Detect variationPredict disease?Improve care?Detection → prediction → utility
A genetic result begins an interpretation process.
Presenter notes · Opening

Open with the clinical tension: sequencing may reveal variation when ultrasound offers no recognizable phenotype. This presentation critically appraises one 2025 meta-analysis using the supplied assessment. It is an educational review, not a new systematic review or an institutional guideline. Suggested duration: 40–50 minutes, including discussion.

Orientation

The clinical decision comes before the technology

Should PES be offered after reassuring anatomy and nondiagnostic chromosome testing?

Population

Apparently structurally normal fetus; conventional testing has not identified an explanation.

Decision

Whether additional sequence information creates enough value to justify broader testing.

Presenter notes · Orientation

PES means prenatal exome sequencing. CMA means chromosomal microarray analysis. The review allowed normal karyotype or CMA; the actual four cohorts all followed a normal CMA. Do not equate reassuring cfDNA screening with normal diagnostic CMA. Ask learners which outcome would change their recommendation: a molecular result, a confirmed childhood diagnosis, or demonstrated improvement in care.

Orientation

Three questions organize the appraisal

By the end, learners should be able to interpret the estimate and use it in counseling.

  1. 01What was detected?

    Read pooled proportions, confidence intervals, and inheritance patterns.

  2. 02What can we predict?

    Assess classification, phenotyping, selection, and follow-up.

  3. 03What should change?

    Apply the evidence to counseling, FGR, practice, and research.

Presenter notes · Orientation

The presentation is designed for MFM clinicians, genetics teams, residents, and fellows. The clinical practice judgments are the supplied appraisal’s interpretation, not recommendations formally issued by the study investigators or an adopted APA policy.

Executive assessment

A small molecular yield; an unresolved clinical benefit

Sotiriadis et al. · Ultrasound Obstet Gynecol. 2025;65(5):552–559.

Any P/LP finding1.6%

Approximately 1 in 63

95% CI 1.0–2.6%

Severe disease-associated0.5%

Approximately 1 in 200

95% CI 0.1–1.5%

Evidence base1,916

Fetuses in four cohorts

32 reported P/LP-positive cases

Presenter notes · Executive assessment

P/LP means pathogenic or likely pathogenic. Reciprocal frequencies are rounded from the pooled point estimates, not from a screening-benefit calculation. A severe disease-associated variant is not a 0.5% proven risk of severe disease in a future child. Severity, penetrance, expressivity, and age at onset require separate evaluation.

Conceptual framework

Detection, prediction, and utility are separate claims

The study directly estimates the first step.

  1. 01Diagnostic yield

    How often was an additional P/LP variant reported?

  2. 02Predictive validity

    Will this fetus develop clinically important disease?

  3. 03Clinical utility

    Does knowing improve decisions, management, or outcomes?

Presenter notes · Conceptual framework

In a phenotype-negative prenatal setting, a molecular finding may establish a diagnosis for some conditions, indicate predisposition for others, or create substantial prognostic uncertainty. We should not assume these possibilities are interchangeable. Clinical utility may include informed reproductive decisions and care planning, not only measurable neonatal treatment effects.

Methods

A registered systematic review of observational cohorts

PROSPERO CRD42024593349 · PRISMA reporting framework.

Search

2018 to September 25, 2024; search repeated before submission. Multiple databases, registers, and reference lists.

Selection

1,030 records → seven full-text articles → four included cohorts. Independent screening and data extraction.

Presenter notes · Methods

Databases included PubMed, Cochrane Library, Google Scholar, Scopus, International HTA, and ClinicalTrials.gov. Inclusion was restricted to English-language reports. Eligible case series required at least 10 fetuses; overlapping samples were checked. These procedures strengthen transparency but cannot repair limitations of the original cohorts.

Methods

Eligibility was broader than the actual evidence

All four included studies were retrospective and used exome sequencing after normal CMA.

Eligible in protocol

Apparently normal fetal phenotype; normal karyotype or CMA; prospective or retrospective cohorts; singleton or twin pregnancies.

Included in practice

Four retrospective cohorts. Mostly trio sequencing; Daum used trio analysis in approximately half of cases.

Presenter notes · Methods

Trio analysis compares fetal and parental sequences and helps identify de novo variants and phase recessive variants. The actual cohorts do not directly establish the same yield after karyotype alone. Clinical selection and the completeness of prenatal assessment differed across studies.

Methods

A single-arm yield analysis cannot test a universal policy

The comparison is the added result after prior testing, without randomized testing strategies.

What it estimates

Frequency of additional reported P/LP findings among fetuses who underwent PES.

What it does not establish

Outcome benefit, causal effects of a testing policy, or the balance of benefit, cost, and psychological burden.

Presenter notes · Methods

Incremental here refers to findings beyond prior conventional testing. It is not a risk difference from a trial of sequencing versus no sequencing. Avoid interpreting the number needed to test to find a variant as a number needed to test to prevent disease or improve outcomes.

Methods

The statistical model fits uncommon events

Random-effects generalized linear mixed model for pooled proportions.

Why GLMM?

Models binomial outcomes directly and handles sparse events without a continuity correction for zero-event studies.

What remains uncertain?

Only four studies inform the between-study distribution. A pooled mean is not a universal patient-specific probability.

Presenter notes · Methods

The investigators used metaprop in R and a random-effects GLMM. Do not treat the pooled 1.6% as the simple arithmetic average of cohort percentages or as an exact population prevalence. A confidence interval describes uncertainty around the pooled estimate; it is not a prediction interval for every new clinical population.

Results

One cohort contributes more than half the fetuses

Cohort counts are observed data; percentages below are crude cohort yields.

CohortCountryFetusesP/LP casesCrude yield
Daum 2023Israel48240.83%
Gao 2024China25462.36%
Levy 2024Israel1,020212.06%
Vaknin 2022Israel16010.63%
Total—1,916321.67%
Presenter notes · Results

The meta-analysis reports these denominators and positive counts in Table 1. Levy provides 53.2% of fetuses and 65.6% of positive cases. Those proportions are not GLMM study weights, which the authors did not calculate. Cohort differences include parental selection, reporting policies, and ultrasound definitions. Do not infer geography explains the differences causally.

Results

Confidence intervals matter as much as point estimates

All estimates are proportions of tested fetuses, not confirmed disease outcomes.

0%1%2%3%Any P/LPSevereModerateDe novo moderate/severe1.6%0.5%0.5%0.7%
Dots: pooled proportions. Lines: 95% CIs. These categories overlap and should not be added.
Presenter notes · Results

Any P/LP: 1.6% (1.0–2.6%); severe: 0.5% (0.1–1.5%); moderate: 0.5% (0.2–1.5%); de novo moderate/severe: 0.7% (0.4–1.2%). The 0.7% subgroup overlaps the overall and severity categories. These estimates are separately pooled and should not be reconstructed by subtracting or adding point estimates. The chart is newly drawn from published summary values, not a reproduction of the article’s forest plot.

Results

Most positive cases involved dominant conditions

Inheritance counts among the 32 P/LP-positive fetuses.

26
Autosomal dominant
5
Autosomal recessive
1
X-linked recessive
Dominant 81.3%Recessive 15.6%X-linked 3.1%
Presenter notes · Results

The separately pooled yields were 1.1% for autosomal dominant findings (95% CI 0.6–2.3%) and 0.3% for autosomal recessive findings (0.1–0.6%). There was only one X-linked recessive case, so its yield could not be robustly pooled. Counts among positives and proportions among all tested fetuses have different denominators.

Results

De novo findings are the most provocative signal

18 de novo variants among 32 positive cases, all in the dominant group.

All de novo findings

0.9%
Pooled yield · 95% CI 0.5–1.7%

De novo + moderate/severe

0.7%
14 fetuses · 95% CI 0.4–1.2%

Presenter notes · Results

Eighteen of 32 positive cases were de novo; eight autosomal dominant variants were inherited, six maternally and two paternally. The 14 moderate/severe de novo cases are a subset, not additional cases. Trio sequencing can recognize these events, but confirming de novo status does not by itself resolve penetrance or clinical severity in this fetus.

Results

Severity describes an associated condition, not a certain outcome

The authors applied or revised severity using the Lazarin framework.

Reported categoryPositive casesPooled yield
Mild9Not pooled: one study
Moderate100.5% (95% CI 0.2–1.5%)
Severe120.5% (95% CI 0.1–1.5%)
Profound1Not pooled: one case
Presenter notes · Results

These counts sum to 32. Severity classification was a post-hoc subanalysis by clinical experts, with reclassification when needed. A universal prenatal disease-severity standard is lacking. Classification concerns the expected associated disease, not a confirmed individual phenotype. The single profound case should not silently be merged into the published severe estimate.

Critical appraisal

Several design choices strengthen the review

Transparent synthesis is useful even when the underlying evidence is limited.

Review process

Registered protocol; systematic search; independent review; explicit inclusion and outcome definitions.

Analysis and interpretation

Appropriate sparse-event model; assessment of inheritance and severity; open acknowledgment of missing outcomes.

Presenter notes · Critical appraisal

Avoid dismissing the paper because it contains only four studies. It provides a baseline for a practice already occurring. Its main strengths are transparency, appropriate synthesis, and clear discussion of interpretive limits. At the same time, some severity and inheritance analyses were post hoc and deserve cautious interpretation.

Critical appraisal · 1

The classification of a “positive” result may change

Independent reanalysis questioned more than half of P/LP variants in one included cohort.

The concern

The authors cite a critique suggesting that over half of the Levy cohort’s P/LP variants could be classified as VUS.

The implication

The 1.6% estimate may overstate robust molecular diagnoses or actionable findings. The magnitude is unresolved.

Presenter notes · Critical appraisal · 1

VUS means variant of uncertain significance; the article also uses VOUS. This was a published independent critique, not a definitive reclassification of every included fetus. The original review notes differences in application of ACMG/ClinGen criteria. A P/LP label evaluates disease causation in a defined context; it is not a guarantee of disease, prognosis, or actionability. The investigators proposed reinterpretation after 24–36 months.

Critical appraisal · 2

Longitudinal phenotype confirmation is missing

No included study confirmed normal phenotype systematically at birth or later pregnancy.

Unknown predictive validity

Which fetuses developed clinically significant disease? Which remained asymptomatic? When did symptoms emerge?

Missing planned analyses

Postnatally confirmed phenotype, uncertain variants, and expected age of onset could not be pooled.

Presenter notes · Critical appraisal · 2

No systematic postnatal confirmation does not mean every molecular result was incorrect or every child lacked follow-up of any kind. It means sufficient data were not reported to perform the review’s planned analyses. Developmental, neurobehavioral, and adult-onset conditions may require years of follow-up.

Critical appraisal · 3

These were selected families in specific health systems

Three of four cohorts were conducted in Israel; one was conducted in China.

Selection by parental request

Reasons varied. Gao’s cohort was strongly enriched for a previous affected child or pregnancy, despite current reassuring assessment.

Different background risk

Routine preconception carrier screening in Israel may reduce observed recessive diagnoses and alter the disease mix.

Presenter notes · Critical appraisal · 3

The population is not equivalent to consecutive unselected patients at routine anatomy screening. A known prior familial disorder was tested before inclusion where relevant, but prior history and parental concerns may still shape selection. Country itself is not the causal factor; screening programs, access, consent, referral patterns, and family selection all matter.

Critical appraisal · 4

“Structurally normal” does not necessarily mean low risk

Definitions and timing of fetal assessment differed across cohorts.

Incomplete phenotyping

Subtle findings, evolving abnormalities, family phenotype, and gestational age may affect interpretation.

Growth is a phenotype

FGR was not consistently or explicitly excluded across the evidence base, although the largest cohort did exclude IUGR.

Presenter notes · Critical appraisal · 4

The review’s discussion identifies incomplete exclusion of FGR as a limitation. Table 1 explicitly lists IUGR among Levy’s exclusions, so saying that no study excluded FGR would be inaccurate. The evidence does not isolate the contribution of growth abnormalities, and it does not provide an isolated-FGR subgroup estimate.

Critical appraisal · 5

The burden of uncertain and secondary findings is unclear

Reporting policies varied; only one study reported VUS.

Uncertain findings

No pooled VUS rate. The psychological and interpretive burden is not quantified.

Secondary findings

Policies differed for fetal versus parental results, childhood versus adult onset, and what counted toward yield.

Presenter notes · Critical appraisal · 5

Gao included adult-onset secondary findings among positive fetal cases, whereas Daum excluded a RET secondary finding from primary diagnoses. The authors note that exchanging selected classifications would leave the headline yield at 1.6%, while changing what that yield means clinically. Discuss consent, future child autonomy, incidental parental findings, and reporting preferences without implying a known rate of harm.

Critical appraisal

Low risk of bias does not establish high certainty

The authors used a modified Newcastle–Ottawa Scale for single-arm cohorts.

What the tool showed

Three studies scored 6/6 stars; one scored 5/6. All were labeled low risk of bias.

What the tool cannot settle

Transportability, variant validity, missing longitudinal outcomes, or the net value of universal testing.

Presenter notes · Critical appraisal

Because these were single-arm cohorts, the comparability section was removed from NOS, reducing the maximum to six stars. The resulting scores are reasonable within that framework. They should not be conflated with high certainty of an individual fetus’s prognosis or a proven clinical benefit of a sequencing program.

Critical appraisal

Clinical utility remains unproven

The review does not establish a net benefit from routine PES in this population.

Potential value

Targeted neonatal assessment, anticipatory planning, reproductive information, and informed family decisions.

Unresolved tradeoffs

Management benefit, cost-effectiveness, uncertainty, psychological effects, and the consequences of broader testing.

Presenter notes · Critical appraisal

Absence of evidence of benefit is not proof of no benefit. Some condition-specific results may be highly useful. The missing claim is that a routine policy creates net benefit across otherwise reassuring pregnancies. This would require management, outcome, patient-reported, and economic evidence beyond variant counts.

Decision analysis

What might testing 10,000 fetuses reveal?

Illustration using pooled point estimates in a comparable population.

Any P/LP finding160

95% CI scaled: 100–260

Severe-associated50

95% CI scaled: 10–150

De novo moderate/severe70

95% CI scaled: 40–120

Presenter notes · Decision analysis

Each number is the published pooled proportion multiplied by 10,000. Scaled CIs describe uncertainty in the expected count from the pooled estimate, not prediction intervals for an actual future cohort. The estimates are not additive. There is no single observed cohort of 10,000 in this paper. The uncertainty range for severe-associated findings is especially wide.

Decision analysis

A 0.5% severe-associated yield supports two reasonable views

The same estimate can be valued differently by different families.

Case for expanded access

A potentially important diagnosis before birth may enable earlier assessment, specialty planning, or reproductive choices.

Case against routine testing

About 99.5% would have no severe-associated finding, while uncertainty, costs, and outcome benefit remain unresolved.

Presenter notes · Decision analysis

The 99.5% complement applies only to the severe-associated finding category. It does not mean 99.5% have no genetic condition, no other finding, or guaranteed normal outcomes. Some families value information highly despite uncertain immediate actionability; others prefer to avoid ambiguous prognostic information. Good counseling makes those preferences explicit.

Practice implications

Three clinical situations require different testing approaches

Practice interpretation for MFM and genetics teams.

Clinical situationApproach
Normal anatomy; no relevant family historyDo not routinely recommend PES on the strength of this meta-analysis alone.
Known familial monogenic disorderOffer testing appropriate to the familial variant; broad PES may be unnecessary.
Structural anomaly; nondiagnostic CMAConsider PES with genetics consultation when a monogenic disorder is suspected.
Presenter notes · Practice implications

These are the supplied critical appraisal’s practice judgments. They are not trial-derived treatment recommendations. Targeted familial testing may be appropriate even with entirely normal anatomy. For structural anomalies, sequence interpretation is strengthened by a defined phenotype. ISPD guidance supports responsible clinical use in selected pregnancies and does not endorse routine sequencing for all pregnancies.

Practice implications

Anomaly-focused sequencing has a different evidence base

The article cites approximately 10% additional yield in unselected structural anomalies.

Unselected structural anomalies

Approximately 10% in early major cohorts after nondiagnostic conventional testing.

Selected phenotypes

Substantially higher yields in selected conditions; the review cites up to 50–68% in some phenotype-specific settings.

Presenter notes · Practice implications

These comparator figures are context cited in the reviewed paper, not new pooled estimates produced by this review. They should not be used as a universal yield for every anomalous fetus or as a head-to-head comparison with the normal-anatomy cohorts. The two populations differ in prior probability and interpretability.

Practice implications

A request for expanded testing deserves a structured discussion

Informed choice can coexist with a recommendation against routine use.

Clarify the question

Reassess imaging, growth, family history, prior diagnostic tests, and what information the family hopes to obtain.

Define the testing plan

Discuss trio analysis, turnaround, limitations, result categories, secondary findings, and genetics follow-up.

Presenter notes · Practice implications

Ask what a result would change, including pregnancy decisions, neonatal planning, or future reproduction. Clarify the laboratory’s reporting policy and options for reinterpretation. Explain that a negative exome does not exclude all genetic disease. Sequencing methods and coverage can miss some variant classes; CMA and exome answer different questions.

Counseling

Explain the yield without promising a diagnosis

Suggested patient-facing language, adapted from the supplied appraisal.

“When the baby’s anatomy appears normal and chromosome testing is reassuring, exome sequencing may find a pathogenic or likely pathogenic genetic change in about 1–2% of cases. A finding does not always tell us whether a child will develop a significant medical condition.”
Presenter notes · Counseling

Use plain language. Pathogenic and likely pathogenic are classifications of a variant’s relationship to disease, not individual outcome guarantees. Some variants have variable penetrance or expression. For a given condition, the evidence may support more or less certainty than this general discussion. Offer written materials and time for genetics counseling.

Counseling

Make the uncertainty and the next step explicit

Suggested continuation of the counseling discussion.

“The estimated chance of finding a change linked to severe disease is about 0.5%, or 1 in 200. These estimates come from small studies. Routine testing in all pregnancies with normal anatomy has not been shown to improve outcomes. A prenatal genetic counselor can help you consider what the information could mean for your family.”
Presenter notes · Counseling

Explain that the severe-associated estimate is imprecise (95% CI 0.1–1.5%) and comes from retrospective selected cohorts. The language is a starting point, not a substitute for individualized informed consent. Ask the patient to explain back the difference between a variant and a predictable outcome, and explore preferences for uncertain or secondary findings.

Fetal growth restriction

Growth restriction can be a meaningful genetic phenotype

Absence of a structural malformation does not establish a low-risk genetic context.

Possible explanations

Placental dysfunction, constitutional smallness, chromosomal disease, or a monogenic condition.

Implication for this review

Inconsistent FGR exclusion complicates the interpretation of a “normal” population.

Presenter notes · Fetal growth restriction

FGR means fetal growth restriction. The review neither proves that FGR caused the reported molecular yield nor establishes a yield for isolated FGR. The correct response is to examine the phenotype carefully, including growth trajectory, Doppler assessment, structural imaging, gestational age, and family history. Do not transfer a 1.6% general pooled estimate into an FGR-specific counseling statistic.

Fetal growth restriction

Keep early severe FGR and late isolated FGR distinct

A framework for individualized assessment, not a new testing algorithm.

Early-onset or severe FGR

Additional concerning findings or an evolving phenotype may increase suspicion for an underlying genetic condition.

Late-onset isolated FGR

Reassuring anatomy and surveillance create a different prior probability and counseling context.

Presenter notes · Fetal growth restriction

Use established FGR evaluation and surveillance pathways. Genetic assessment may include diagnostic chromosome testing and, in selected circumstances, molecular testing after specialist consultation. This presentation intentionally does not invent an FGR sequencing threshold from a study that did not analyze the relevant subgroup.

Research agenda

The next study should confirm disease and usefulness

A prospective multicenter design should connect variant detection with lived outcomes.

  1. 01Standardize entry

    Imaging, growth, family history, prior testing, and consecutive recruitment.

  2. 02Standardize interpretation

    Trio sequencing, consistent classification, reporting rules, and reinterpretation.

  3. 03Follow through childhood

    Confirm phenotype, penetrance, clinical consequences, and delayed onset.

Presenter notes · Research agenda

A larger denominator alone will not solve uncertain variant validity and missing follow-up. A useful prospective registry or comparative study should record the pathway from pretest indication through result disclosure, management decisions, birth, and childhood. Systematically document nonparticipation and attrition to assess selection and follow-up bias.

Research agenda

Measure outcomes beyond the number of variants

A sequencing program must be evaluated as a care pathway.

Clinical and prognostic outcomes

  • Confirmed clinically significant diagnoses
  • Changes in prenatal and neonatal management
  • Penetrance, severity, and age at onset

Patient and system outcomes

  • Uncertain, incidental, and secondary findings
  • Psychological effects and decisional regret
  • Costs, access, and cost-effectiveness
Presenter notes · Research agenda

Comparative designs can test whether sequencing alters care or outcomes relative to usual pathways; universal randomization may not be the only feasible design. Record whether a change in management was beneficial, neutral, or harmful, not merely whether a change occurred. Patient-reported outcomes should respect differing values rather than presuming all additional information is either good or bad.

Overall judgment

Promising, not practice-changing

Qualitative appraisal of the evidence supplied for this review.

DomainAssessment
Clinical relevanceHigh
Methodological rigorGood
Sample sizeLimited
Certainty of reported diagnostic yieldModerate to low
Evidence of clinical benefitInsufficient
Immediate impact on routine practiceLimited
Presenter notes · Overall judgment

These qualitative domain ratings are the supplied appraisal’s interpretation and not a formal GRADE profile. Diagnostic yield is subject to uncertain variant classification and selected recruitment. Clinical benefit is not disproven; it is insufficiently evaluated. Avoid calling this a practice-changing trial or a screening guideline.

Implementation

Use the evidence for education before changing policy

Proposed actions for APA and OpenMFM; not an adopted institutional policy.

APA

Incorporate estimates and limitations into prenatal genetics counseling and provider education. This study alone does not support universal PES.

OpenMFM

Teach the distinction between diagnostic yield, predictive validity, and clinical utility through this evidence review.

Presenter notes · Implementation

APA refers to the organization named in the supplied brief, consistent with Atlanta Perinatal Associates in existing repository branding. These proposed recommendations should not be displayed as an official policy already approved by APA. Decisions about offering and funding testing require local clinical governance and up-to-date guidance.

Journal club

A result arrives; what has been diagnosed?

Hypothetical case for discussion.

A fetus has normal anatomy and nondiagnostic CMA. Trio PES identifies a P/LP variant linked to a variably penetrant dominant condition.

Discuss

Have we established disease, identified predisposition, or created a category of prenatal uncertainty?

Before advising

What condition-specific evidence, parental phenotype, laboratory review, and follow-up plan would change the interpretation?

Presenter notes · Journal club

No real patient is represented. Do not ask learners to resolve an unnamed variant without the gene, variant evidence, inheritance details, and phenotype. The teaching goal is recognizing what information is missing. Condition-specific consultation may support a firm diagnosis, a probabilistic risk estimate, or a need for reinterpretation and observation.

Journal club

Three checks for interpreting the paper

Use these prompts before translating the findings into a recommendation.

1 · Can 160, 50, and 70 be added?

No. The per-10,000 categories overlap and are separately pooled.

2 · Is 0.5% a confirmed severe-disease risk?

No. It is the yield of variants associated with a severe disease category.

3 · Can we quote 1.6% for isolated FGR?

No. No isolated-FGR subgroup yield was established.

Presenter notes · Journal club

Use this as a brief knowledge check or ask the audience to answer before revealing the slide. The denominators, categories, and distinction between findings and disease are the highest-value interpretation skills in this review. Each answer should connect to a specific limitation in the methods or source evidence.

Take-home message

Counsel with the estimate; preserve the uncertainty

Our ability to detect variation exceeds our ability to predict all of its consequences.

Overall P/LP yield1.6%

A baseline for counseling.

Severe-associated yield0.5%

A meaningful but uncertain signal.

Clinical benefit

Unproven

Universal PES is not established.

Presenter notes · Take-home message

Return to the opening question. This paper advances the evidence for prenatal genomic detection but does not establish the case for universal exome sequencing in structurally normal pregnancies. The 0.7% moderate/severe de novo signal deserves further study, especially because carrier screening does not reliably anticipate those events. The appropriate response is better counseling and better outcome evidence.

References

Primary evidence and interpretation

The article’s tables, results, and discussion underpin the quantitative appraisal.

  1. Primary study · Sotiriadis et al. 2025Sotiriadis A, Demertzidou E, Ververi A, et al. Incremental yield of exome sequencing over standard prenatal testing in structurally normal fetuses: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2025;65(5):552–559. doi:10.1002/uog.29195.Read source
  2. Included cohort · Levy et al. 2024Levy M, Lifshitz S, Goldenberg-Fumanov M, et al. Exome sequencing in every pregnancy? Results of trio exome sequencing in structurally normal fetuses. Prenat Diagn. 2024. doi:10.1002/pd.6585.Read source
  3. Included cohort · Gao et al. 2024Gao Z, Zhu X, Ren H, Wang Y, Hua C, Kong X. Prenatal exome sequencing for morphologically normal fetus: should we be doing it? Prenat Diagn. 2024. doi:10.1002/pd.6624.Read source
  4. Interpretation critique · Chandler et al. 2024Chandler N, Holder-Espinasse M, Mone F. The challenges of performing exome sequencing in structurally normal fetuses. Prenat Diagn. 2024. doi:10.1002/pd.6687.Read source
Presenter notes · References

The included cohort counts and reported diagnostic categories were verified against the open-access article. Primary cohort details and critiques are linked for deeper review. This slideshow synthesizes the supplied appraisal and the named sources; it is not a comprehensive update of studies published after the review’s search.

References

Methods, severity, and professional context

Evidence review prepared November 12, 2026; primary review search ended in 2024.

  1. Reporting framework · PRISMA 2020Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med. 2021;18(3):e1003583.Read source
  2. Severity framework · Lazarin et al. 2014Lazarin GA, Hawthorne F, Collins NS, Platt EA, Evans EA, Haque IS. Systematic classification of disease severity for evaluation of expanded carrier screening panels. PLoS One. 2014;9(12):e114391.Read source
  3. Variant interpretation · Richards et al. 2015Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the ACMG and AMP. Genet Med. 2015;17(5):405–424. doi:10.1038/gim.2015.30.Read source
  4. Practice context · ISPD 2022Van den Veyver IB, Chandler N, Wilkins-Haug LE, Wapner RJ, Chitty LS; ISPD. International Society for Prenatal Diagnosis Updated Position Statement on the use of genome-wide sequencing for prenatal diagnosis. Prenat Diagn. 2022;42(6):796–803. doi:10.1002/pd.6157.Read source
Presenter notes · References

Sources support different claims: PRISMA addresses reporting, ACMG/AMP addresses variant interpretation, Lazarin supplies a severity framework, and ISPD supplies clinical context. Do not infer that any one of these documents endorses routine sequencing in otherwise low-risk pregnancies. The deck reviews the specified 2025 paper rather than claiming to summarize all evidence available in 2026.

References

  1. Primary study · Sotiriadis et al. 2025Sotiriadis A, Demertzidou E, Ververi A, et al. Incremental yield of exome sequencing over standard prenatal testing in structurally normal fetuses: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2025;65(5):552–559. doi:10.1002/uog.29195.Read source
  2. Included cohort · Levy et al. 2024Levy M, Lifshitz S, Goldenberg-Fumanov M, et al. Exome sequencing in every pregnancy? Results of trio exome sequencing in structurally normal fetuses. Prenat Diagn. 2024. doi:10.1002/pd.6585.Read source
  3. Included cohort · Gao et al. 2024Gao Z, Zhu X, Ren H, Wang Y, Hua C, Kong X. Prenatal exome sequencing for morphologically normal fetus: should we be doing it? Prenat Diagn. 2024. doi:10.1002/pd.6624.Read source
  4. Interpretation critique · Chandler et al. 2024Chandler N, Holder-Espinasse M, Mone F. The challenges of performing exome sequencing in structurally normal fetuses. Prenat Diagn. 2024. doi:10.1002/pd.6687.Read source
  5. Reporting framework · PRISMA 2020Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med. 2021;18(3):e1003583.Read source
  6. Severity framework · Lazarin et al. 2014Lazarin GA, Hawthorne F, Collins NS, Platt EA, Evans EA, Haque IS. Systematic classification of disease severity for evaluation of expanded carrier screening panels. PLoS One. 2014;9(12):e114391.Read source
  7. Variant interpretation · Richards et al. 2015Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the ACMG and AMP. Genet Med. 2015;17(5):405–424. doi:10.1038/gim.2015.30.Read source
  8. Practice context · ISPD 2022Van den Veyver IB, Chandler N, Wilkins-Haug LE, Wapner RJ, Chitty LS; ISPD. International Society for Prenatal Diagnosis Updated Position Statement on the use of genome-wide sequencing for prenatal diagnosis. Prenat Diagn. 2022;42(6):796–803. doi:10.1002/pd.6157.Read source

Quantitative values verified against the 2025 open-access review. Scope: critical appraisal of this paper, not a living evidence update.